The inherently complex interaction between insulin’s direct effects, the inherent severity of T2D in insulin-treated individuals, and the influence of concurrent fat accretion makes its net contribution to preventing or treating sarcopenia questionable compared to treatments that produce fat loss with the additional potential of having a more neutral or even a positive influence upon the fat-to-lean mass ratio. The gene discussed is INS; the disease is type 2 diabetes mellitus.